X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ORCHID PHARMA LTD - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH ORCHID PHARMA LTD PANACEA BIOTECH/
ORCHID PHARMA LTD
 
P/E (TTM) x 176.4 -0.5 - View Chart
P/BV x 3.9 0.4 1,033.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   ORCHID PHARMA LTD
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
ORCHID PHARMA LTD
Sep-13
PANACEA BIOTECH/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs149194 76.6%   
Low Rs8235 235.1%   
Sales per share (Unadj.) Rs84.1276.5 30.4%  
Earnings per share (Unadj.) Rs-18.3-79.2 23.1%  
Cash flow per share (Unadj.) Rs-6.7-43.5 15.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.753.9 155.2%  
Shares outstanding (eoy) m61.2570.45 86.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.40.4 331.4%   
Avg P/E ratio x-6.3-1.4 436.5%  
P/CF ratio (eoy) x-17.2-2.6 654.3%  
Price / Book Value ratio x1.42.1 65.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0748,067 87.7%   
No. of employees `0002.82.8 98.2%   
Total wages/salary Rs m1,4492,527 57.3%   
Avg. sales/employee Rs Th1,874.16,956.1 26.9%   
Avg. wages/employee Rs Th527.0902.5 58.4%   
Avg. net profit/employee Rs Th-407.7-1,993.0 20.5%   
INCOME DATA
Net Sales Rs m5,15419,477 26.5%  
Other income Rs m100407 24.5%   
Total revenues Rs m5,25419,884 26.4%   
Gross profit Rs m-7661,103 -69.5%  
Depreciation Rs m7112,519 28.2%   
Interest Rs m1,5035,227 28.8%   
Profit before tax Rs m-2,881-6,236 46.2%   
Minority Interest Rs m1120 54.8%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771511 346.6%   
Tax Rs m17-125 -13.4%   
Profit after tax Rs m-1,121-5,580 20.1%  
Gross profit margin %-14.95.7 -262.7%  
Effective tax rate %-0.62.0 -29.1%   
Net profit margin %-21.8-28.7 75.9%  
BALANCE SHEET DATA
Current assets Rs m3,81011,014 34.6%   
Current liabilities Rs m8,36532,060 26.1%   
Net working cap to sales %-88.4-108.1 81.8%  
Current ratio x0.50.3 132.6%  
Inventory Days Days15695 164.1%  
Debtors Days Days6734 200.4%  
Net fixed assets Rs m14,48029,440 49.2%   
Share capital Rs m61705 8.7%   
"Free" reserves Rs m9032,043 44.2%   
Net worth Rs m5,1273,800 134.9%   
Long term debt Rs m5,8329,018 64.7%   
Total assets Rs m19,43346,510 41.8%  
Interest coverage x-0.9-0.2 474.6%   
Debt to equity ratio x1.12.4 47.9%  
Sales to assets ratio x0.30.4 63.3%   
Return on assets %2.0-0.8 -258.4%  
Return on equity %-21.9-146.9 14.9%  
Return on capital %3.6-3.7 -97.4%  
Exports to sales %24.537.9 64.7%   
Imports to sales %10.222.6 45.0%   
Exports (fob) Rs m1,2647,378 17.1%   
Imports (cif) Rs m5254,406 11.9%   
Fx inflow Rs m1,5397,513 20.5%   
Fx outflow Rs m9425,649 16.7%   
Net fx Rs m5971,865 32.0%   
CASH FLOW
From Operations Rs m5991,682 35.6%  
From Investments Rs m-438-9,860 4.4%  
From Financial Activity Rs m-3036,644 -4.6%  
Net Cashflow Rs m-141-1,535 9.2%  

Share Holding

Indian Promoters % 74.5 32.3 230.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 4.6 13.0%  
FIIs % 1.3 3.3 39.4%  
ADR/GDR % 0.0 4.6 -  
Free float % 23.6 55.3 42.7%  
Shareholders   10,259 84,811 12.1%  
Pledged promoter(s) holding % 35.1 54.9 63.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 16, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS